Company Update (NYSE:PFE): FDA expands use of Pfizer’s best-selling pneumonia vaccine

[Reuters] – Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49. The vaccine, which is already approved for use in adults aged 50 and above, and children aged 6 weeks to 17 years, prevents invasive diseases caused by 13 Streptococcus pneumoniae strains. Prevnar has been buoying Pfizer’s revenue, helping the company beat Wall Street estimates. Read more on this. , currently valued at $recting to http://finance.ya, finished yesterday at $. Today, shares have traded between $ per share and has traded between $ over the past year. Priced at x this year’s forecasted earnings, PFE shares are relatively inexpensive compared to the industry’s x forward p/e ratio. Consensus earnings for the current quarter by the 0 sell-side analysts covering the stock is an estimate of $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $, which would be a $0.00 setback when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $0.00 . If reported, that would be a 0.00% decrease over the year-ago quarter. In terms of ratings, d PFE from to (/fi). Previously, d PFE from to . When considering if the stock is under or overvalued, the average price target is $, which is 0.00% below where the stock opened this morning. See more in (NYSE:PFE) Similar Articles: Partnerships Propel Stellar Biotechnologies’ Vaccine Technology Company Update (NYSE:CI): Cigna Builds on Three Years of Success, Expands Genetic Counseling Program Company Update (NYSE:UNH): UnitedHealthcare Community Plan Expands Service Area; Now Available in 43 New York Counties